close
Add to watchlist
Rosetta Genomics Ltd (ROSG)
Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of minimally/non-invasive, blood or serum-based molecular diagnostics tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer and chronic infections. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the company's microRNA-based cancer diagnostic tests; and a testing and administrative services agreement with Teva Pharmaceutical Industries Ltd. to distribute these tests in Turkey and Israel. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.30 |
| Volume | 82699 |
| Volume Avg | 304774 |
| 52 Week High | 2.43 |
| 52 Week Low | 0.13 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | 0.00 |
| EPS change Q/Q | -66.67% |
| EPS change Q/Q Yr ago | -69.57% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -53.33% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |